Recruiting

Testing a medication to reduce inflammation and prevent heart damage in kidney disease

Plain-English translation of NCT06203977 on ClinicalTrials.gov ↗ · Source last updated March 2025 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This study is testing whether , a medication that reduces inflammation, can help protect the hearts and kidneys of people with advanced chronic kidney disease. Researchers will enroll 200 adults — some with severe kidney disease who don't yet need dialysis, and others who are already on regular dialysis — and follow them for about 4 months to see how well they tolerate the medication and whether it causes them to stop taking it.

People with chronic kidney disease face a higher risk of heart and blood vessel problems, partly because of harmful inflammation in the body. Doctors hope that this medication, which is known to reduce inflammation, might help prevent these serious complications.

Do you qualify?

You likely qualify if…

you have very advanced chronic kidney disease (with a measured kidney function level of 30 or lower) that has been confirmed at least twice over 2 months, and you are not expected to need dialysis in the next 6 months, OR you are already receiving dialysis at least twice per week and have been doing so for the past 3 months
you are 18 years old or older
you are willing to provide informed consent and understand what the study involves

You likely don't qualify if…

you are currently taking colchicine and medically need to stay on it
you have a known allergy or past bad reaction to colchicine
you are pregnant, planning to become pregnant, or breastfeeding during the study
you have liver disease (cirrhosis or chronic active hepatitis), ongoing severe diarrhea, or a nerve and muscle disease
you have recently had blood work (within 60 days) showing very low white blood cells, very low platelets, or very high liver enzymes

What participation looks like

You would take a daily oral medication at a starting dose for 8 weeks. If you tolerate it well, the dose would be increased for another 8 weeks. You'll be followed for a total of about 17 weeks to track how you're doing and whether you experience any side effects. The main goal is to see how many people can continue taking the medication without having to stop it.

AI-generated summary from trial data · Jun 3, 2026 · Not medical advice

Trial locations(3 sites)

Canada

University of Alberta Hospital, Edmonton, Alberta

St. Joseph's Healthcare Hamilton, Hamilton, Ontario

London Health Sciences Centre, London, Ontario